title: Growth of human myeloid leukemias in the human marrow environment of SCID-hu mice.
abstract: It has been shown previously that multilineage human hematopoiesis is maintained within human fetal bone marrow (BM) fragments implanted into severe combined immunodeficient (SCID) mice. We describe here an application of this animal model, the SCID-hu mouse, to the study of human myeloid leukemias. BM cells from 8 patients with various types of myeloid leukemias were injected directly into human bone grafts in the SCID-hu mouse. Cells from 7 patients grew in the human marrow without spreading to the mouse marrow. Cells from 6 of these patients were successfully transferred in vivo to secondary SCID-hu recipients. The surface phenotype and the cytologic features of the leukemia cells were conserved during passage in vivo. Thus, human myeloid leukemia cells could be reproducibly propagated in the human marrow environment in SCID-hu mice. The differentiation of promyelocytic leukemia cells in the SCID-hu mice was induced by all-trans retinoic acid, suggesting that the biologic features of the leukemia cells were maintained as well. Finally, evidence for a leukemic progenitor cell population in one case of acute myelogenous leukemia was provided with this system. This model may provide a useful tool for studying the biology of human myeloid leukemia as well as for evaluating new therapeutic modalities for myeloid leukemias.
authors.affiliation: New Enterprise Research Division, SyStemix Inc., Palo Alto, CA.
authors.forename: R
authors.initials: R
authors.lastname: Namikawa
authors.forename: R
authors.initials: R
authors.lastname: Ueda
authors.forename: S
authors.initials: S
authors.lastname: Kyoizumi
mesh_terms: D000818:Animals; D015703:Antigens, CD / Q000032:analysis; D015214:Antigens, Differentiation, Myelomonocytic / Q000032:analysis; D001853:Bone Marrow / Q000473:pathology*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D007951:Leukemia, Myeloid / Q000188:drug therapy / Q000276:immunology / Q000473:pathology*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D015479:Leukemia, Myelomonocytic, Acute / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D016256:Lewis X Antigen; D051379:Mice; D016513:Mice, SCID; D009368:Neoplasm Transplantation; D063268:Sialic Acid Binding Ig-like Lectin 3; D014183:Transplantation, Heterologous; D014212:Tretinoin / Q000627:therapeutic use
chemical_list: D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; C571163:CD33 protein, human; C571165:Cd33 protein, mouse; D016256:Lewis X Antigen; D063268:Sialic Acid Binding Ig-like Lectin 3; D014212:Tretinoin